MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Viatris Inc

Chiusa

SettoreSettore sanitario

9.24 -0.32

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

9.2

Massimo

9.35

Metriche Chiave

By Trading Economics

Entrata

-2.5B

-3B

Vendite

-274M

3.3B

Rendimento da dividendi

5.38

Margine di Profitto

-93.476

Dipendenti

32,000

EBITDA

-2.7B

-2.3B

Raccomandazioni

By TipRanks

Raccomandazioni

Vendi

Previsioni per 12 mesi

-2.81% downside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

5.38%

2.40%

Utili prossimi

7 ago 2025

Prossima data del Dividendo

12 set 2025

Prossima data del' Ex Dividendo

22 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

950M

11B

Apertura precedente

9.56

Chiusura precedente

9.24

Notizie sul Sentiment di mercato

By Acuity

50%

50%

328 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Viatris Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 lug 2025, 15:46 UTC

I principali Market Mover

BitMine Shares Fall After Closing of $250 Million Private Placement

9 lug 2025, 23:44 UTC

Discorsi di Mercato

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 lug 2025, 23:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

9 lug 2025, 23:42 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 lug 2025, 22:59 UTC

Discorsi di Mercato

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 lug 2025, 22:59 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

9 lug 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

9 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 lug 2025, 20:26 UTC

Utili

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 lug 2025, 19:18 UTC

Discorsi di Mercato

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 lug 2025, 19:03 UTC

Discorsi di Mercato

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 lug 2025, 18:31 UTC

Discorsi di Mercato

Some Fed Officials Supported Considering July Cut -- Market Talk

9 lug 2025, 17:07 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 lug 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk -2-

9 lug 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

9 lug 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

9 lug 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 lug 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

9 lug 2025, 16:14 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

9 lug 2025, 16:14 UTC

Discorsi di Mercato

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 lug 2025, 16:14 UTC

Acquisizioni, Fusioni, Takeovers

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 lug 2025, 16:12 UTC

Discorsi di Mercato

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 lug 2025, 16:08 UTC

Discorsi di Mercato

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 lug 2025, 15:31 UTC

I principali Market Mover

BitMine Shares Fall After Closing of $250M Private Placement

9 lug 2025, 15:31 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 lug 2025, 15:27 UTC

Discorsi di Mercato

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 lug 2025, 14:36 UTC

Acquisizioni, Fusioni, Takeovers

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 lug 2025, 14:31 UTC

Acquisizioni, Fusioni, Takeovers

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 lug 2025, 14:26 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

9 lug 2025, 14:26 UTC

Discorsi di Mercato

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Confronto tra pari

Modifica del prezzo

Viatris Inc Previsione

Obiettivo di Prezzo

By TipRanks

-2.81% in calo

Previsioni per 12 mesi

Media 9 USD  -2.81%

Alto 10 USD

Basso 8 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Viatris Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Vendi

3 ratings

0

Acquista

2

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

8.48 / N/ASupporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Very Strong Bullish Evidence

A lungo termine

Strong Bearish Evidence

Sentiment

By Acuity

328 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.